Suppr超能文献

交感神经系统在肥胖相关高血压中的作用。

The role of the sympathetic nervous system in obesity-related hypertension.

作者信息

da Silva Alexandre A, do Carmo Jussara, Dubinion John, Hall John E

机构信息

Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4505, USA.

出版信息

Curr Hypertens Rep. 2009 Jun;11(3):206-11. doi: 10.1007/s11906-009-0036-3.

Abstract

Obesity is recognized as a major health problem throughout the world. Excess weight is a major cause of increased blood pressure in most patients with essential hypertension and greatly increases the risk for diabetes, cardiovascular diseases, and end-stage renal disease. Although the mechanisms by which obesity raises blood pressure are not completely understood, increased renal sodium reabsorption, impaired pressure natriuresis, and volume expansion appear to play important roles. Several potential mechanisms have been suggested to contribute to altered kidney function and hypertension in obesity, including activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system, as well as physical compression of the kidneys, especially when visceral obesity is present. Activation of the sympathetic nervous system in obesity may be due, in part, to hyperleptinemia and other factors secreted by adipocytes and the gastrointestinal tract, activation of the central nervous system melanocortin pathway, and baroreceptor dysfunction.

摘要

肥胖被公认为是全球主要的健康问题。超重是大多数原发性高血压患者血压升高的主要原因,并且极大地增加了患糖尿病、心血管疾病和终末期肾病的风险。尽管肥胖导致血压升高的机制尚未完全明确,但肾钠重吸收增加、压力性利钠受损和血容量扩张似乎起着重要作用。已有几种潜在机制被认为与肥胖时肾功能改变和高血压有关,包括交感神经系统和肾素 - 血管紧张素 - 醛固酮系统的激活,以及肾脏受到物理压迫,尤其是存在内脏肥胖时。肥胖时交感神经系统的激活可能部分归因于高瘦素血症以及脂肪细胞和胃肠道分泌的其他因素、中枢神经系统黑皮质素途径的激活和压力感受器功能障碍。

相似文献

1
The role of the sympathetic nervous system in obesity-related hypertension.
Curr Hypertens Rep. 2009 Jun;11(3):206-11. doi: 10.1007/s11906-009-0036-3.
2
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
Circ Res. 2015 Mar 13;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.
3
Pathophysiology of obesity hypertension.
Curr Hypertens Rep. 2000 Apr;2(2):139-47. doi: 10.1007/s11906-000-0073-4.
4
Impact of the obesity epidemic on hypertension and renal disease.
Curr Hypertens Rep. 2003 Oct;5(5):386-92. doi: 10.1007/s11906-003-0084-z.
5
Role of leptin and central nervous system melanocortins in obesity hypertension.
Curr Opin Nephrol Hypertens. 2013 Mar;22(2):135-40. doi: 10.1097/MNH.0b013e32835d0c05.
6
Pathophysiology and treatment of obesity hypertension.
Curr Pharm Des. 2004;10(29):3621-37. doi: 10.2174/1381612043382855.
7
Role of sympathetic nervous system and neuropeptides in obesity hypertension.
Braz J Med Biol Res. 2000 Jun;33(6):605-18. doi: 10.1590/s0100-879x2000000600001.
8
Is obesity a major cause of chronic kidney disease?
Adv Ren Replace Ther. 2004 Jan;11(1):41-54. doi: 10.1053/j.arrt.2003.10.007.
9
The kidney, hypertension, and obesity.
Hypertension. 2003 Mar;41(3 Pt 2):625-33. doi: 10.1161/01.HYP.0000052314.95497.78. Epub 2003 Jan 20.
10
The Role of Aldosterone in Obesity-Related Hypertension.
Am J Hypertens. 2016 Apr;29(4):415-23. doi: 10.1093/ajh/hpw003. Epub 2016 Feb 28.

引用本文的文献

1
Association between triglyceride-glucose index multiplied by waist circumference and H-type hypertension among Chinese adults.
Front Cardiovasc Med. 2025 Jul 10;12:1589488. doi: 10.3389/fcvm.2025.1589488. eCollection 2025.
3
Inflammasomes: novel therapeutic targets for metabolic syndrome?
Front Endocrinol (Lausanne). 2025 May 13;16:1569579. doi: 10.3389/fendo.2025.1569579. eCollection 2025.
4
The Combined Effect of Smoking and Obesity on Hypertension: Implications for Clinical Management.
Curr Hypertens Rev. 2025;21(1):2-14. doi: 10.2174/0115734021351026250126165154.
9
Objective Home-Monitoring of Physical Activity, Cardiovascular Parameters, and Sleep in Pediatric Obesity.
Digit Biomark. 2022 Mar 31;6(1):19-29. doi: 10.1159/000522185. eCollection 2022 Jan-Apr.

本文引用的文献

1
Modulation of blood pressure by central melanocortinergic pathways.
N Engl J Med. 2009 Jan 1;360(1):44-52. doi: 10.1056/NEJMoa0803085. Epub 2008 Dec 17.
2
Mediators of sympathetic activation in metabolic syndrome obesity.
Curr Hypertens Rep. 2008 Dec;10(6):440-7. doi: 10.1007/s11906-008-0083-1.
3
Sympathetic nervous system behavior in human obesity.
Neurosci Biobehav Rev. 2009 Feb;33(2):116-24. doi: 10.1016/j.neubiorev.2008.05.024. Epub 2008 May 28.
4
Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation.
Endocrinology. 2008 Aug;149(8):4183-92. doi: 10.1210/en.2008-0255. Epub 2008 May 1.
6
Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats.
Hypertension. 2008 Apr;51(4):884-90. doi: 10.1161/HYPERTENSIONAHA.107.100636. Epub 2008 Feb 19.
7
Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension?
Hypertension. 2008 Feb;51(2):168-71. doi: 10.1161/HYPERTENSIONAHA.107.090514. Epub 2007 Dec 17.
8
Adiponectin, cardiovascular function, and hypertension.
Hypertension. 2008 Jan;51(1):8-14. doi: 10.1161/HYPERTENSIONAHA.107.099424. Epub 2007 Nov 12.
9
Prolonged activation of the baroreflex abolishes obesity-induced hypertension.
Hypertension. 2007 Jun;49(6):1307-14. doi: 10.1161/HYPERTENSIONAHA.107.087874. Epub 2007 Apr 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验